More to follow!
More to follow!
Exploring Sjogren's Videos, Sjogren's Foundation
Highly recommended. Videos one and two of the Season One series are a must see for newly diagnosed patients and their friends and family.
CITATIONS
1. Helmick CG, Felson DT, Lawrence RC, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part I. Arthritis Rheum 2008;58: 15-25.
https://onlinelibrary.wiley.com/doi/full/10.1002/art.23177
2. Vivino, F. B. (2017). Sjogren’s syndrome: Clinical aspects. 2017;182: 48–54.
https://doi.org/10.1016/j.clim.2017.04.005
3. Brito-zerón, P, Theander, E, Baldini, C. et al, Quartuccio, L, Bootsma, H, … Fox, R. Early diagnosis of primary Sjögren’ s syndrome : EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016; 12(2): 137–156.
https://www.ncbi.nlm.nih.gov/pubmed/26691952
4. Criswell, LA, Shiboski, C H, Shiboski, SC, Labetoulle, M, Lietman,TM, Rasmussen, A, … Mariette, X. (2016). American College of Rheumatology / European League Against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome.Arthritis Rheum 2017; 69(1): 35-45.
https://onlinelibrary.wiley.com/doi/full/10.1002/art.39859
5.Bournia V-K, Vlachoyiannopoulous PG. Subgroups of Sjogren syndrome patients according to serologic profiles. Journal of Autoimmunity 2012;39: 15-26.
https://www.ncbi.nlm.nih.gov/pubmed/22575069
6/ Didlier K, Bloko L, et al. Autoantibodies Associated with Connective Tissue Diseases: What Meaning for Clinicians? Front Immunol 2018;9: 1-20.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879136/
7. Carsons S (1998) The New Sjogren’s Syndrome Handbook Carsons,S, Harris E (Eds.) New York: The Medical Workup of Sjogren's Syndrome. Oxford University Press.
8. Demarchi J, Papasidero S, Medina,MA, et al. Primary Sjogren’s syndrome: Extraglandular manifestations and hydroxychloroquine therapy. Clin Rheum 2017;36(11): 2455-2460.
https://www.ncbi.nlm.nih.gov/pubmed/28913747
9. Shen, L., Suresh, L., Lindemann, M., Xuan, J., Kowal, P., Malyavantham, K., & Ambrus, J. L., Jr (2012). Novel autoantibodies in Sjogren's syndrome. Clinical immunology (Orlando, Fla.), 145(3), 251–255. h
https://www.ncbi.nlm.nih.gov/pubmed/23123440
10. Ng, WF (ed). (2016) Sjogren's Syndrome. Oxford, UK: Oxford University Press
11. Baldini C, Ferro F, Elefante E. Bombardieri S. Biomarkers for Sjogren’s Syndrome. Biomark Med 2018;12(3): 275-286.
https://www.ncbi.nlm.nih.gov/pubmed/29460647
12.Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman S, Dorner T…Vitali C. on behalf of EULAR Sjogren Syndrome Task Force.Characterization of systemic disease in primary Sjogren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 2015;54: 2230-2238.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281074/
13. Sheikh S, Shaw-Stiffel T. The gastrointestinal manifestations of Sjogren’s syndrome. Am J Gastroenterol 1995; 90(1): 9-14.
https://www.ncbi.nlm.nih.gov/pubmed/7801957
14. Fox RI. Advances in understanding, diagnosing and treating Sjogren syndrome.
https://www.medscape.com/viewarticle/848782
15. Beckman KA, Luchs J, Milner MS, Ambrus JL Jr. The potential role for early biomarker testing as part of a modern, multidisciplinary approach to Sjogren’s syndrome diagnosis. Adv Ther 2017;34(4): 799-812.
https://core.ac.uk/display/81617896 (Open Access)
16. Ferro F, Vagelli R, Bruni C, Cafaro G, Marcucci E, Bartoloni E, Baldini C. One year in review 2016: Sjogren’s syndrome. Clin Exp Rheumatol 2016;34: 161-171.
https://pubmed.ncbi.nlm.nih.gov/27095672/
17. Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown R, Morgan P, Bombardieri S…Barone F on behalf of the Sjogren’s histopathology workshop group, EULAR Sjogren’s syndrome study group. Standardization of labial salivary gland histopathology in clinical trials in primary Sjogren’s Syndrome. Ann Rheum Dis 2017;76: 1161-1168.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530351/
18. Fox, PC. Is a lip biopsy 100 % accurate? The Moisture Seekers, March 2008.(p.17)
http://www.sjogrens.org/files/tms/tms2008-03.pdf
19. Serin G, Karabulut G, Kabasakal Y, Kandiloglu G, Akalin T. The importance of minor salivary gland biopsy in Sjogren syndrome diagnosis and the clinicopathological correlation. Turk Patoloji Derg. 2016;32(2):65-9.
http://www.turkjpath.org/text.php3?doi=10.5146/tjpath.2015.01346
20. Reksten TR, Jonsson MV. Sjogren’s syndrome: An update on epidemiology and current insights on pathophysiology. Oromaxillofacial Surg Clin N Am 2014;26(1): 1-12
https://www.ncbi.nlm.nih.gov/pubmed/24287189
21. Akpek EK, Bunya VY, Saldanha IF. Ocular manifestations of primary Sjogren’s: what you don’t know might surprise you. Sjogren’s Quarterly; 13 (3) Summer 2018.
22. Hammitt KM, Naegeli AN, van den Broek, RWM, Birt, JA. Patient burden of Sjogren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity. Rmdopen2017; 3(2)-e000443
https://rmdopen.bmj.com/content/3/2/e000443
23. Rasmussen A, Radfar L, Lewis D, Grundahl K, Stone DU, Kaufman CE, … Scofiled RH. Previous diagnosis of Sjogren’s syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology 2016 Jul;55(7): 1195-201.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281033/
24. Brito-Zeron, P, Ramos-Casals M.Systemic Sjogrens: More than a sicca disease.
https://www.the-rheumatologist.org/article/systemic-sjgrens-more-than-a-sicca-disease/
25. Sjogren’s Syndrome Foundation.Breakthrough Goal survey results 2016. Polaris Marketing Research; 2016.
26. Ng, Wan-Fai.Primary Sjogren’s syndrome: Too dry and too tired. Rheumatology 2010;49: 844-853.
https://www.ncbi.nlm.nih.gov/pubmed/20147445
27. Segal G, Bowman S et al. Primary Sjogren’s syndrome: health experiences and predictors of health quality among patients in the United States.Health Qual Life Outcomes. 2009 ;7:46
https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-7-46
28. Dusenbery, M. Doing Harm. 2018, New York: HarperCollins
29. http://simpletasks.org/wp-content/uploads/2018/08/Rheumatic-Disease-Report-Card-US.pdf
30. Brito-Zeron P, Ramos-Casals M, et al. Predicting adverse outcomes in primary Sjogren’s syndrome: identification of prognostic factors. Rheumatology 2007;46:1359-1362
https://www.ncbi.nlm.nih.gov/pubmed/17569749
32. McCoy SS, Baer AN.Neurological Complications of Sjogren’s Syndrome: Diagnosis and Management. Curr Treatm Opt Rheumatol 2017; 3(4):275-288
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322693/pdf/nihms-986304.pdf
33. Goodman BP, Crepeau A, Dhawan PS, Khoury JA, Harris L. Spectrum of autonomic nervous system impairment in Sjogren syndrome. The Neurologist 2017;22:127-130.
https://www.ncbi.nlm.nih.gov/pubmed/28644253
34. Bunya, VY, Fernandez, KG et al. Survey of ophthalmologists regarding practice patterns for dry eye and Sjogren syndrome. Eye & Contact Lens 2018;44:S196-S201.
https://www.ncbi.nlm.nih.gov/pubmed/29369232
35. Akpek EK, Mathews, P et al. Ocular and systemic morbidity in a longitudinal cohort of Sjogren’s syndrome Ophthalmology 2015;122:56-61
https://www.ncbi.nlm.nih.gov/pubmed/25178806
36. Kabasakal Y, Kitapcioglu G et al. Criteria sets for primary Sjogren’s syndrome are not adequate for those presenting with extraglandular organ involvements as their dominant clinical features. Rheumatol Int (2017) 37:675–684
https://www.ncbi.nlm.nih.gov/pubmed/28289872
37. Seror R, Bowman SJ, Brito-Zeron P…Mariette X, on behalf of the EULAR Sjogren’s Task Force.EULAR Sjogren’s Syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015;1:e000022.
https://rmdopen.bmj.com/content/1/1/e000022 (Open Access)
38. Ramos-Casals M, Brito-Zeron P… Kostov B on behalf of the SS Study Group and Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine. Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 2014;53:321-331
https://www.ncbi.nlm.nih.gov/pubmed/24162151
39. Flament T, Bigot A Chaigne et al. Pulmonary manifestations of Sjogren’s syndrome. European Respiratory Review 2016; 25: 110-123
https://err.ersjournals.com/content/25/140/110
40. Alpek EK, Bunya VY, Saldanha IJ. Sjogren’s Syndrome: More than just dry eye. Cornea 2019 Jan 22.
https://www.ncbi.nlm.nih.gov/pubmed/30681523
41. Tiensvoll AB, Goransson LG. High headache-related disability in patients with systemic lupus erythematosus and primary Sjogren’s syndrome. Eur J Neurol 2014;21(8):1124-30
https://tinyurl.com/y5hpjra2
42. Brito-Zeron P, Baldini C, Bootsma H…Ramos-Casals M. Sjogren’ Syndrome. 2016 Nature Reviews Disease Primers. 2016;2:1-20.
https://www.ncbi.nlm.nih.gov/pubmed/27383445
43. Sutcliffe N, Stoll T et al. Functional disability and end-organ damage in patients with systemic lupus and Sjogren’s syndrome. J Rheumatol 1998;25(1):63-68
https://www.ncbi.nlm.nih.gov/pubmed/9458204
44. Strömbeck B, Ekdahl C, Manthorpe R, et al. Health-related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol. 2000; 29(1):20–281.
https://www.ncbi.nlm.nih.gov/pubmed/10722254
45. Mirouse A, Seror, Vicaut E… Mekinian A on behalf of Club Rheumatismes Inflammation and SNFMI. Arthritis in primary Sjogren’s syndrome: Characteristics, outcome, and treatment from a French multicenter retrospective study. Autoimmun Rev. 2019 Jan;18(1):9-14
https://www.ncbi.nlm.nih.gov/pubmed/30408585
46. Wallace, DJ. (2012). Sjogren’s Syndrome Foundation. Oxford, UK: Oxford University Press.
47. Both T, Dalm VASH, van Hagen PM, van Daele PLA. Reviewing primary Sjogren’s syndrome:beyond the dryness- From pathophysiology to diagnosis and treatment. Int J Med Sci 2017; (14):191-200.
http://www.medsci.org/v14p0191.htm
48.Tjensvoll AB.(2016). Headache in systemic lupus erythematosus and primary Sjogren’s syndrome.
(Doctoral dissertation, University of Bergen -link no longer available)
49. Ng W-F, Stangroom AJ, Davidson A, Wilton K, Mitchell S, Newton JL. Primary Sjogrens syndrome is associated with impaired autonomic response to orthostasis and sympathetic failure. Q J Med 2012; 105:1191-1199.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508582/ (Open Access)
50. Newton, JL, Frith J, Powell … Ng, WF on behalf of the UK primary Sjogren’s syndrome registry. Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren’s Syndrome. Ann Rheum Dis 2012;71: 1973-1979
https://www.ncbi.nlm.nih.gov/pubmed/22562982 (Open Access)
51. Koh JH, Kwok SK, Lee Jet al. Autonomic dysfunction in primary Sjogren’s syndrome: a prospective cohort analysis of 154 Korean patients. Korean J Intern Med 2017;32:165-173
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214725/pdf/kjim-2015-219.pdf
52. Mori K, Iijima M, Koike H…Sobue G.The wide spectrum of clinical manifestations in Sjogren syndrome-associated neuropathy. Brain 2005; 128: 2518-2534.
https://www.ncbi.nlm.nih.gov/pubmed/16049042
53. Kovacs L, Paprika, D, Takacs R,. Pokorny G. Cardiovascular autonomic dysfunction in primary Sjogren’s syndrome. Rheumatology 2004;43(1):95-99
https://www.ncbi.nlm.nih.gov/pubmed/12949253
54. Stojan G, Baer AN, Danoff SK. Pulmonary manifestations of Sjogren’s syndrome. Curr Allergy Asthma Rep 2013; 13(4); 354-360.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393654/pdf/nihms-674901.pdf
55. Ocon Aj, Messer ZR, Medow MS, Stewart JM. Increasing orthostatic stress impairs neurocognitive functioning in chronic fatigue syndrome. Clin Sci 2012: 122 (5):227-238.
56. Carsons SE, Vivino FB, Parke A…Mandel S. Treatment guidelines for Rheumatologic manifestations of Sjogren’s: Use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res 2017: Apr;69(4):517-527.
https://www.ncbi.nlm.nih.gov/pubmed/27390247
57.Price EH, Rauz S, Tappuni AR… Bowman, SJ; on behalf of the British Society for Rheumatology Standards, Guideline and Audit Working Group. The British Society for Rheumatology guideline for management of adults with primary Sjogren’s syndrome. Rheumatology. 2017: Oct 1;56(10):1828
https://www.ncbi.nlm.nih.gov/pubmed/28957572
58. Price EJ, Baer AN. How to treat Sjogren’s syndrome. Rheumatology, 2019, Feb. 15. (epub ahead of print)
https://pubmed.ncbi.nlm.nih.gov/30770917/
59. Thomas Jr., DE. The Lupus Encyclopedia, a Comprehensive Guide for Patients and Families. 2014. Johns Hopkins University Press.
60. Hernandez-Molina G, Valim V...Catalan-Pellet A. Do antimalarials protect against damage accrual in primary Sjogren's syndrome? Results from a Latin-American retrospective cohort. Clin Exp Rheumatol 2018;36 (Suppl.112):S182-S185
https://www.clinexprheumatol.org/article.asp?a=12439 (Open Access)
61. Brito-Zeron P, Kostov B, Solans R... Ramos-Casals M. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2016;75:348-355.
https://www.ncbi.nlm.nih.gov/pubmed/25433020
62. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum, 2000 Apr; 29 (5):296-304
https://pubmed.ncbi.nlm.nih.gov/10805354/
63. Retamozo S, Acar- Denizli N, Rasmussen A...Brito-Zeron, P. Systemic manifestations of primary Sjogren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large, international, multi-ethnic cohort of patients. Clin Exp Rheumatol 2019; 37 (Suppl. 118):S97-S106.
https://www.clinexprheumatol.org/article.asp?a=14220
64. James, J. A., Guthridge, J. M., Chen, H., Lu, R., Bourn, R. L., Bean, K., Munroe, M. E., Smith, M., Chakravarty, E., Baer, A. N., Noaiseh, G., Parke, A., Boyle, K., Keyes-Elstein, L., Coca, A., Utset, T., Genovese, M. C., Pascual, V., Utz, P. J., Holers, V. M., … St Clair, E. W. (2020). Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford, England), 59(4),860–868. https://doi.org/10.1093/rheumatology/kez335
https://www.ncbi.nlm.nih.gov/pubmed/31497844 (Open Access)
65. Imgenberg-Kreuz J, Almlof JC, Leonard D,...Nordmark G. Shared and unique patterns of DNA methylation in systemic lupus erythematosus and primary Sjogren's Syndrome. Front Immunol 2019;10:1686.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688520/
66. Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjogren syndrome. Nat Rev Rheumatol 2018 Mar;14(34):133-145
https://www.ncbi.nlm.nih.gov/pubmed/29416129
67. Bombardieri M, BaldiniC ...Baer AN. Highlights of the 14th International Symposium on Sjogren's Syndrome. Clin Exp Rheumatol 2018;36 (Suppl. 112): S3-S13:675-684.
https://www.clinexprheumatol.org/article.asp?a=13089 (Open Access)
68. Varan O, Babaoglu H, Goker B. Associations between depressive disorders and inflammatory rheumatic diseases. Curr Top Med Chem 2018;18(16):1395-1401
https://www.ncbi.nlm.nih.gov/pubmed/29766809
69. Akpek EK, Bunya VY, Saldanha IJ. Sjogren's syndrome: more than just dry eye. Cornea 2019;00:1-4.
https://pubmed.ncbi.nlm.nih.gov/30681523/ (Open Access)
70. Konty E, Lewandowska-Poluch A, Chmielinska M, Olesinkska M. Subgroups of Sjogren's syndrome patients categorised by serological profiles: clinical and immunological characteristics.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330679/
71. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases. Nat Rev Rheumatol 2014;11: 86-97
https://www.nature.com/articles/nrrheum.2014.193
72. Harris VM, Scofield RH, Sivils KL. Genetics in Sjogren's syndrome: where are we and where will we go. Clin Exp Rheumatol 2019; 37 (Suppl. 118): S234-S239.
https://www.ncbi.nlm.nih.gov/pubmed/31464674 (Open Access)
73. Tsirves GK, Voulgari PV, Pelechas E, Asimakopoulos AD, Drosos AA. Cochlear involvement in patients with systemic autoimmune rheumatic diseases: a clinical and laboratory comparative study. Eur Arch Otorhinolayrngo. 2019;276(9):2419-2426
https://www.ncbi.nlm.nih.gov/pubmed/31175453
74. Applbaum E, Lichtbroun A. Novel Sjogren's autoantibodies found in fibromyalgia patients with sicca and/or xerostomia. Autoimmun Rev 2019 Feb 18(2):199-202 .
https://www.ncbi.nlm.nih.gov/pubmed/30572137
75. Elliott G, Spence AR, Czurzoj-Shulman N, Abenhaim HA. Effect of Sjogren's syndrome on maternal and neonatal outcomes of pregnancy. J Perinatal Med 2019;47(6): 637-642
https://pubmed.ncbi.nlm.nih.gov/31287800/
76. Yazisiz V, Gocer M, Ebrasan F...Terzioglu ME. Survival analysis of patients with Sjogren's syndrome in Turkey: a tertiary hospital-based study. Clin Rheumatol 2019 Sept. 25 (Epub ahead of print)
https://www.ncbi.nlm.nih.gov/pubmed/31555987
77. Aggarwal R, Ringold S, Khanna D...Feldman BM. Distinctions between diagnostic and classification criteria. Arthritis Care Res 2015;67(7):891-897
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482786/
78. Alunno A, Bartoloni E...Gerli R. Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjogren's syndrome. Clin Exp Rheumatol 2018;36 (Suppl.112): S210-S214.
https://www.clinexprheumatol.org/article.asp?a=12955
79. Vivino F, Bunya V, Massaro-Giordano G, AmbrusJr, JL. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol 203 (2019) 81-121.
https://www.ncbi.nlm.nih.gov/pubmed/31022578
80. Maciel G, Servioli L, Nannini C...Cornec D. Hospitalisation rates among patients with primary Sjogren's syndrome: a population-based study, 1995-2016. RMD Open 2018;4:e000575.
https://rmdopen.bmj.com/content/4/1/e000575
81. Abrol E, Gonzelez-Pulido C, Praena-Fernandez HN, Isenberg DA. A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience. Clin Med 2014;14(2):157-164.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4953287/
82. Walsh N, Wilson, FP, Caputo D. Sjogren's carries heavy disease burden. April 26, 2013. BSR meeting coverage. (Presentation based on citation 81,with additional commentary).
https://www.medpagetoday.org/meetingcoverage/bsr/38713?vpass=1
83. Al-Ezzi M, Khan K, Tappuni AR. Is the taste acuity affected by oral dryness in primary Sjogren's syndrome patients? Oral Dis Dec 19 (Epub ahead of print)
https://www.ncbi.nlm.nih.gov/pubmed/31856365
84. Trevisani VFM, Pasoto SG, Fernandes MLMS...Valim V. Recommendations from the Brazilian society of rheumatology for the diagnosis of Sjogren's syndrome (Part I): glandular manifestations (systematic review). Advances in Rheumatology 2019; 59:58 .
https://www.ncbi.nlm.nih.gov/pubmed/31852541 (Open Access)
85. Moreira I, Teixeira, Silva AM, Santos E. Frequent involvement of the central nervous system in primary Sjogren syndrome. Rheumatol Int 2015;53:289-294
www.ncbi.nlm.nih.gov/pubmed/25056402
86. Manzo C, Martinez-Suarez E, Kechids M, Isetta M, Serra-Mestres K. Cognitive function in primary Sjogren's syndrome: A systematic review. Brain Sci 2019;9(4):85
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523842/ (Open Access)
87. Birnbaum, J. Clinical peripheral nervous system manifestations of Sjogren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis and therapeutic strategies. Neurologist 2010;16(5):287-297.
https://www.ncbi.nlm.nih.gov/pubmed/20827117
88. Omdal R, Mallegren SI, Norheim KB. Pain and fatigue in primary Sjogren's syndrome. Rheumatology, 2019. (epub pages 1-8).
https://www.ncbi.nlm.nih.gov/pubmed/30815693
89. Sambataro G, Ferro F, Orlandi M..Matucci CM. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjogren's syndrome: A systematic review from the Italian Society of Rheumatology. 2019 Dec 14 (Epub ahead of print)
https://doi.org/10.1016/j.autrev.2019.102447
90. Guisado-Vasco P, Silva M, Duarte-Millán MA, Sambataro G, Bertolazzi C, et al. (2019) Quantitative assessment of interstitial lung disease in Sjögren’s syndrome. PLOS ONE 14(11): e0224772.
https://doi.org/10.1371/journal.pone.0224772 (Open Access)
91. Mengshoel AM, Norheim KB, Omdal R. Primary Sjogren's syndrome: fatigue is an ever-present, fluctuating, and uncontrollable lack of energy. Arthritis Care Res 2014;66:1227-32.
https://onlinelibrary.wiley.com/doi/full/10.1002/acr.22263 (Open Access)
92. Brito-Zeron P, Acar Denizli N, Ng WF...Trevisani VFM. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjogren's syndrome. Rheumatology 2019;0:1-10 (E pub ahead of print)
https://www.ncbi.nlm.nih.gov/pubmed/31873754
93. Brito-Zeron P, Acra-Denizli, N, Zeher M...Ramos-Casals M. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjogren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjogren Project Consortium. Ann Rheum Dis 2017;76:1042-50.
https://ard.bmj.com/content/76/6/1042
94. McCormick N, Marra CA... Avina-Zubietta JA. Excess productivity costs of systemic lupus erythematosus, systemic sclerosis, and Sjogren's syndrome: a general population-based study. Arthritis Care Res 2019;71(1):142-154.
https://www.ncbi.nlm.nih.gov/pubmed/29648677
95. Radfar L, Kleiner DE, Fox PC, Pillemer SR. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 2002; 47(5):520-524.
https://onlinelibrary.wiley.com/doi/full/10.1002/art.10668 (Open Access)
96. Cafaro G, Croia C, Argyopoulou OD...Bartoloni E. One year in review 2019: Sjogren's syndrome. Clin Exp Rheumatol 2019;37 (Suppl.118): S3-S15).
https://www.clinexprheumatol.org/article.asp?a=14480 (Open Access)
97. Vasaitis L, Nordmark G, Theander E...Baecklund E. Comparison of patients with and without pre-existing lymphoma at diagnosis of Sjogren's syndrome. Scand J Rheumatol 2019;48(3):207-212.
98. Living with Sjogren’s Survey 2016: Summary of major findings.
https://www.sjogrens.org/sites/default/files/inline-files/LivingwithSjogrens-8.5x11Bifold-2020.pdf
99. Park EH, Strand V…Lee EB. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. Arth Res Ther 2019;21:61.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377714/ (Open Access)
100. Segal B, Thomas W…Moser K. Prevalence, severity, and predictors of fatigue in subjects with primary Sjogren’s syndrome. Arthritis Rheum 2008;59 (12):1780-7.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106978/ (Open Access)
101. Segal BM, Pogatchnik B…Moser KL. Primary Sjogren’s syndrome: cognitive symptoms, mood and cognitive performance. Acta Neurol Scand 2012;125(4):272-8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188671/ (Open Access)
102 Uffmann, M., Kiener, H. P., Bankier, A. A., Baldt, M. M., Zontsich, T., & Herold, C. J. (2001). Lung manifestation in asymptomatic patients with primary Sjögren syndrome: assessment with high resolution CT and pulmonary function tests. Journal of thoracic imaging, 16(4), 282–289. https://doi.org/10.1097/00005382-200110000-00009
https://pubmed.ncbi.nlm.nih.gov/11685093/
103. Bartoloni E, Baldini C…Gerli R. Cardiovascular disease risk burden in primary Sjogren’s syndrome: results of a population-based multicenter cohort study. J Intern Med 2015;278: 185-192.
https://www.ncbi.nlm.nih.gov/pubmed/25582881 (Open Access)
104. Bartoloni E, Alunno A…Gerli R. Subclinical atherosclerosis in primary Sjogren’s syndrome: Does inflammation matter? Front Immunol 2019 Apr 17;10:817
https://www.ncbi.nlm.nih.gov/pubmed/31110500 (Open Access)
105. Avina-Zubieta JA, Jansz M, Sayre EC, Choi HK. The risk of deep venous thrombosis and pulmonary embolism in primary Sjogren syndrome: A general population-based study. J Rheumatol 2017 Aug;44(8):1184-1189.
https://www.ncbi.nlm.nih.gov/pubmed/28298559 (Open Access)
106. Tsai YD, Chien WC, Tsai SH...Wang JC. Increased risk of aortic aneurysm and dissection in patients with Sjogren’s syndrome: a nationwide population-based cohort study in Taiwan. BMJ Open 2018;8:e022326
https://bmjopen.bmj.com/content/8/9/e022326 (Open Access)
107. Brom M, Moyano S..Soriano ER. Incidence of cancer in a cohort of patients with primary Sjogren syndrome in Argentina. Rheumatol Int 2019;39(10):1697-1702.
https://www.ncbi.nlm.nih.gov/pubmed/31471716
108. Chang CC, Lin TM…Chen JH. Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Ann Med 2018;50(1): 83-90.
https://www.ncbi.nlm.nih.gov/pubmed/29224375
109. Hou TY, Hsu HC…Chen JH. Higher risk of dementia in primary Sjogren’s syndrome. Ann Clin Transl Neurol 2019;6(4):633-641.
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.737 (Open Access)
110. Anaya JM, Restrepo-Jimenez P…Mantilla RD. Sjogren’s syndrome and thyroid disease: two sides of the same coin. Clin Rev Allergy Immunol 2019 Jun;56(3):362-374.
https://www.ncbi.nlm.nih.gov/pubmed/30187363
111. Bartoloni E, Bistoni O…Gerli R. Celiac disease prevalence is increased in primary Sjogren’s syndrome and diffuse systemic sclerosis: lessons from a large multi—center study. J Clin Med 2019;8(4):1-14.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517955/ (Open Access)
112. Parreau, S., Jacques, J., Dumonteil, S., Palat, S., Geyl, S., Gondran, G., Bezanahary, H., Liozon, E., Azaïs, J., Colombie, S., Jauberteau, M. O., Loustaud-Ratti, V., Ly, K. H., & Fauchais, A. L. (2021). Abdominal symptoms during Sjogren's syndrome: a pilot study. Advances in rheumatology (London, England), 61(1), 5.
https://doi.org/10.1186/s42358-021-00164-w
https://pubmed.ncbi.nlm.nih.gov/33468262/
113. Brito-Zeron P, Retamozo S, Ramos-Casals M. Phenotyping Sjogren's syndrome: towards a personalised management of the disease. Clin Exp Rheumatol 2018;36 (Suppl.112): S198-S209.
https://www.clinexprheumatol.org/article.asp?a=12950 (Open Access)
114. Tzioufas AG, Goules AV. Limited efficacy of targeted treatments in Sjogren's syndrome: why? Clin Exp Rheumatol 2018; 36(Suppl.112): S27-S28.
https://www.clinexprheumatol.org/article.asp?a=12868 (Open Access)
115.Bjerrum K, Prause JU. Primary Sjogren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 1990;8(3): 283-288.
http://europepmc.org/article/MED/2379343
116 Flores-Chavez A, Kostov B ... Ramos-Casals M. Severe, life-threatening phenotype of primary Sjogrens syndrome: clinical characterisation and outcomes in 1580 patients (GEWAS-SS Registry). Clin Exp Rheumatol 2018;36 (Suppl 112): S121-S129.
https://www.clinexprheumatol.org/abstract.asp?a=12884 (Open Access)
117. Baldini C, Pepe P... Bombardieri. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2013;53: 839-844.
https://pubmed.ncbi.nlm.nih.gov/24369420
118. Gottenberg JE, Seror R...Mariette X. Serum levels of Beta2-microblobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PloS One 2013;8: 1-6
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663789/ (Open Access)
119. Brito-Zeron P, Acar-Denizli N...Ramos-Casals M, Sjogren Big Data Consortium. How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project).
Clin Exp Rheumatol 2018;36 Suppl. 112): S102-S112.
https://www.clinexprheumatol.org/article.asp?a=12899 (Open Access)
120. Brunetta E, Shiffer D...Furlan R. Autonomic abnormalities in patients with primary Sjogren's syndrome- preliminary results. Front Physiol 2019; 10: 1-13.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736624/pdf/fphys-10-01104.pdf (Open access)
121. Quartuccio L, Gandolfo S...De Vita S. Articular and peripheral nervous system involvement are linked to the long-term outcome in primary Sjogren's syndrome: the relevance of single organ manifestations rather than a composite score as predictors. Front Immunol 2019;10:1527
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637305/ (Open Access)
122. Kollert F, Fisher BA. Equal rights in autoimmunity: is Sjogren’s syndrome ever “secondary”? Rheumatology 2020:0:1-8 (epub ahead of print)
https://pubmed.ncbi.nlm.nih.gov/32025734
123. Anaya JM, Rojas-Villarraga A... Sarmiento-Monroy JC. Polyautoimmunity in Sjogren Syndrome. Rheum Dis Clin North Am 2016; 42 (3):457-472.
https://pubmed.ncbi.nlm.nih.gov/27431348
124. Pego-Reigosa JM, Restrepo Velez J, et al. Comorbidities (excluding lymphoma) in Sjogren's Syndrome. [published online ahead of print, 2019 Feb 15]. Rheumatology (Oxford). 2019;key329.
https://pubmed.ncbi.nlm.nih.gov/30770715/
125. Chang CC, Chang YS, Wang SH, Lin SY, Chen YH, Chen JH. Primary Sjogren's syndrome and the risk of acute pancreatitis: a nationwide cohort study. BMJ Open. 2017;7(8):e014807. Published 2017 Aug 11. doi:10.1136/bmjopen-2016-014807
https://pubmed.ncbi.nlm.nih.gov/28801391/
126. Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42(9):968-978.
https://pubmed.ncbi.nlm.nih.gov/22827853/
127. Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: An old drug with new relevance. Cleve Clin J Med. 2018;85(6):459-467. https://pubmed.ncbi.nlm.nih.gov/29883308/
128. Mena-Vázquez N, Fernández-Nebro A, Pego-Reigosa JM, et al. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry [published online ahead of print, 2019 Dec 6]. Rheumatology (Oxford). 2019;kez562.
https://pubmed.ncbi.nlm.nih.gov/31808534/ (Open Access)
129. Fox RI, Fox CM, Gottenberg JE, Dörner T. Treatment of Sjögren's syndrome: current therapy and future directions [published online ahead of print, 2019 Apr 26]. Rheumatology (Oxford). 2019;kez142. doi:10.1093/rheumatology/kez142
https://pubmed.ncbi.nlm.nih.gov/31034046/
130. Wang SQ, Zhang LW, Wei P, Hua H. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2017;18(1):186. Published 2017 May 12.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427554/ (Open Access)
131. Valim V, Trevisani VF, Pasoto SG, et al. Recommendations for the treatment of Sjögren's syndrome. Rev Bras Reumatol. 2015;55(5):446-457.
https://pubmed.ncbi.nlm.nih.gov/26360421/
132. Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi:10.1136/annrheumdis-2019-216114
https://ard.bmj.com/content/annrheumdis/79/1/3.full.pdf
133. Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC. Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. QJM. 2019;112(10):757-762. doi:10.1093/qjmed/hcz112
https://pubmed.ncbi.nlm.nih.gov/31218368/
134. Both T, Zillikens MC, Schreuders-Koedam M, et al. Hydroxychloroquine affects bone resorption both in vitro and in vivo. J Cell Physiol. 2018;233(2):1424-1433. doi:10.1002/jcp.26028
https://pubmed.ncbi.nlm.nih.gov/28556961/
135. Liu D, Li X, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:1685-1695.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001837/ (Open Access)
136. Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249-258.
https://pubmed.ncbi.nlm.nih.gov/25027140/
137. Tarn JR, Howard-Tripp…Gottenberg JE. Symptom-based stratification of patients with primary Sjogren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomized clinical trials. Lancet Rheumatol 2019; 1: e85-94.
https://www.thelancet.com/action/showPdf?pii=S2665-9913%2819%2930042-6 (Open Access)
138. Jaskólska M, Chylińska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjögren's syndrome: a preliminary report. Rheumatol Int. 2020;40(8):1267-1274. doi:10.1007/s00296-020-04543-2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316843/ (Open Access)
139. Yazisiz V, Aslan B, Erbasan F, Uçar İ, Öğüt TS, Terzioğlu ME. Clinical and serological characteristics of seronegative primary Sjögren's syndrome: a comparative study [published online ahead of print, 2020 Jun 5]. Clin Rheumatol. 2020;10.1007/s10067-020-05154-9.
https://pubmed.ncbi.nlm.nih.gov/32504193/
140. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394. doi:10.1016/j.ophtha.2016.01.058
https://pubmed.ncbi.nlm.nih.gov//26992838/
https://ontariorheum.ca/images/uploads/content_documents/OPHTHA_2011_MarmorMarmor2011dj_AAO_plaquenil.pdf (Open Access)
141. Narváez, J., Sánchez-Fernández, S. Á., Seoane-Mato, D., Díaz-González, F., & Bustabad, S. (2020). Prevalence of Sjögren's syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases. Scientific reports, 10(1), 10627. https://doi.org/10.1038/s41598-020-67462-z
https://pubmed.ncbi.nlm.nih.gov//32606345/
142. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017;31(6):828-845. doi:10.1038/eye.2016.298
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518824/ (Open Access)
143. Thomas, D. E., Lyons, J. S., Greene, B. S., & Petri, M. A. (2019). Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. Lupus science & medicine, 6(1), e000335.
https://doi.org/10.1136/lupus-2019-000335 (Open Access)
144. Dos Reis Neto, E. T., Kakehasi, A. M., de Medeiros Pinheiro, M., Ferreira, G. A., Marques, C., da Mota, L., Dos Santos Paiva, E., Pileggi, G., Sato, E. I., Reis, A., Xavier, R. M., & Provenza, J. R. (2020). Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in rheumatology (London, England), 60(1), 32. https://doi.org/10.1186/s42358-020-00134-8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202/pdf/42358_2020_Article_134.pdf
145. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210-219. doi:10.1097/MD.0b013e318181e6af
https://pubmed.ncbi.nlm.nih.gov/18626304/ (Open Access)
146. Dai, F., Yang, G., Rao, P., Wu, P., Chen, R., Sun, Y., Peng, Y., Qian, H., Wang, B., Chen, S., Liu, Y., & Shi, G. (2020). Clinical Characteristics of Secondary Immune Thrombocytopenia Associated With Primary Sjögren's Syndrome. Frontiers in medicine, 7, 138. https://doi.org/10.3389/fmed.2020.00138
https://pubmed.ncbi.nlm.nih.gov//32363196/ (Open Access)
147. Gyöngyösi, M., Pokorny, G., Jambrik, Z., Kovács, L., Kovács, A., Makula, E., & Csanády, M. (1996). Cardiac manifestations in primary Sjögren's syndrome. Annals of the rheumatic diseases, 55(7), 450–454. https://doi.org/10.1136/ard.55.7.450
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1010208/
148. Mandl,T., Ekberg, O., Wollmer, P., Manthorpe, R., & Jacobsson, L. T. (2007). Dysphagia and dysmotility of the pharynx and oesophagus in patients with primary Sjögren's syndrome. Scandinavian journal of rheumatology, 36(5), 394–401. https://doi.org/10.1080/03009740701607638
https://pubmed.ncbi.nlm.nih.gov/17963171/
149. Levine T. D. (2018). Small Fiber Neuropathy: Disease Classification Beyond Pain and Burning. Journal of central nervous system disease, 10, 1179573518771703. https://doi.org/10.1177/1179573518771703
150. Heus, A., Arends, S., Van Nimwegen, J. F., Stel, A. J., Nossent, G. D., & Bootsma, H. (2020). Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI. Scandinavian journal of rheumatology, 49(1), 38–46. https://doi.org/10.1080/03009742.2019.1634221
https://pubmed.ncbi.nlm.nih.gov/31556344/
151. Vivino F. (2020) Sjogren’s Syndrome: A Clinical Handbook. Amsterdam: Elsevier.
152. Larssen, E., Brede, C., Hjelle, A., Tjensvoll, A. B., Norheim, K. B., Bårdsen, K., Jonsdottir, K., Ruoff, P., Omdal, R., & Nilsen, M. M. (2019). Fatigue in primary Sjögren's syndrome: A proteomic pilot study of cerebrospinal fluid. SAGE open medicine, 7, 2050312119850390. https://doi.org/10.1177/2050312119850390
https://pubmed.ncbi.nlm.nih.gov/31205695/
153. Parisis, D., Chivasso, C., Perret, J., Soyfoo, M. S., & Delporte, C. (2020). Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy. Journal of clinical medicine, 9(7), 2299. https://doi.org/10.3390/jcm9072299
https://pubmed.ncbi.nlm.nih.gov/32698400/
https://www.mdpi.com/2077-0383/9/7/2299/htm (Open Access)
154. Jain, A., Srinivas, B. H., Emmanuel, D., Jain, V. K., Parameshwaran, S., & Negi, V. S. (2018). Renal involvement in primary Sjogren's syndrome: a prospective cohort study. Rheumatology international, 38(12), 2251–2262. https://doi.org/10.1007/s00296-018-4118-x
https://pubmed.ncbi.nlm.nih.gov/30155666/
155. François, H., & Mariette, X. (2016). Renal involvement in primary Sjögren syndrome. Nature reviews. Nephrology, 12(2), 82–93. https://doi.org/10.1038/nrneph.2015.174
https://pubmed.ncbi.nlm.nih.gov/26568188/
156. Mathews, P. M., Robinson, S. A., Gire, A., Baer, A. N., & Akpek, E. K. (2020). Extraglandular ocular involvement and morbidity and mortality in primary Sjögren's Syndrome. PloS one, 15(9), e0239769. https://doi.org/10.1371/journal.pone.0239769
https://pubmed.ncbi.nlm.nih.gov/32976549/ (Open Access)
157. Servioli, L., Maciel, G., Nannini, C., Crowson, C. S., Matteson, E. L., Cornec, D., & Berti, A. (2019). Association of Smoking and Obesity on the Risk of Developing Primary Sjögren Syndrome: A Population-based Cohort Study. The Journal of rheumatology, 46(7), 727–730. https://doi.org/10.3899/jrheum.180481
https://pubmed.ncbi.nlm.nih.gov/30647188/
158. Nilsson, A. M., Diaz, S., Theander, E., Hesselstrand, R., Piitulainen, E., Ekberg, O., Wollmer, P., & Mandl, T. (2015). Chronic obstructive pulmonary disease is common in never-smoking patients with primary Sjögren syndrome. The Journal of rheumatology, 42(3), 464-471. https://doi.org/10.3899/jrheum.140370
https://pubmed.ncbi.nlm.nih.gov/25593235/
159. Lee, A. S., Scofield, R. H., Hammitt, K. M., Gupta, N., Thomas, D. E., Moua, T., Ussavarungsi, K., St Clair, E. W., Meehan, R., Dunleavy, K., Makara, M., Carsons, S. E., & Carteron, N. L. (2020). Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest, S0012-3692(20)34902-3. Advance online publication. https://doi.org/10.1016/j.chest.2020.10.011
https://pubmed.ncbi.nlm.nih.gov/33075377/ (Open Access)
160. Ramírez Sepúlveda, J. I., Kvarnström, M., Eriksson, P., Mandl, T., Norheim, K. B., Johnsen, S. J., Hammenfors, D., Jonsson, M. V., Skarstein, K., Brun, J. G., DISSECT consortium, Rönnblom, L., Forsblad-d'Elia, H., Magnusson Bucher, S., Baecklund, E., Theander, E., Omdal, R., Jonsson, R., Nordmark, G., & Wahren-Herlenius, M. (2017). Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients. Biology of sex differences, 8(1), 25. https://doi.org/10.1186/s13293-017-0146-6
https://pubmed.ncbi.nlm.nih.gov/28789696/ (Open Access)
161. Hammitt K. M. (2020). Sjögren's: the patients' perspective. Clinical and experimental rheumatology, 38 Suppl 126(4), 25–26.
https://pubmed.ncbi.nlm.nih.gov/33025897/ (Open Access)
162. Strömbeck, B., & Jacobsson, L. T. (2007). The role of exercise in the rehabilitation of patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome. Current opinion in rheumatology, 19(2),197–203. https://doi.org/10.1097/BOR.0b013e32801494e3
https://pubmed.ncbi.nlm.nih.gov/17278938/
163. Strömbeck, B. E., Theander, E., & Jacobsson, L. T. (2007). Effects of exercise on aerobic capacity and fatigue in women with primary Sjogren's syndrome. Rheumatology (Oxford, England), 46(5), 868–871. https://doi.org/10.1093/rheumatology/kem004
https://pubmed.ncbi.nlm.nih.gov/17308315/
164. Wang, B., Chen, S., Zheng, Q., Li, Y., Zhang, X., Xuan, J., Liu, Y., & Shi, G. (2021). Early diagnosis and treatment for Sjögren's syndrome: current challenges, redefined disease stages and future prospects. Journal of autoimmunity, 117, 102590. https://doi.org/10.1016/j.jaut.2020.102590
https://pubmed.ncbi.nlm.nih.gov/33310686/
165. Ramos-Casals, M., Brito-Zerón, P., Perez-De-Lis, M., Jimenez, I., Blanco, M. J., Bove, A., Soto, M. J., Akasbi, M., Diaz, C., Sentís, J., & Siso, A. (2010). Sjögren syndrome or Sjögren disease? The histological and immunological bias caused by the 2002 criteria. Clinical reviews in allergy & immunology, 38(2-3),178–185. https://doi.org/10.1007/s12016-009-8152-z
https://pubmed.ncbi.nlm.nih.gov/19578996/
166. Mulhearn, B., Tansley, S. L., & McHugh, N. J. (2020). Autoantibodies in connective tissue disease. Best practice & research. Clinical rheumatology, 34(1), 101462. https://doi.org/10.1016/j.berh.2019.101462
https://pubmed.ncbi.nlm.nih.gov/31848055/
167. Huang, H., Xie, W., Geng, Y., Fan, Y., & Zhang, Z. (2021). Mortality in patients with primary Sjögren's syndrome: A systematic review and meta-analysis. Rheumatology (Oxford, England), keab364. Advance online publication. https://doi.org/10.1093/rheumatology/keab364
https://pubmed.ncbi.nlm.nih.gov/33878179/
168. Rodrigues, A. R., & Soares, R. (2017). Inflammation in Sjögren's syndrome: Cause or consequence?. Autoimmunity, 50(3), 141–150. https://doi.org/10.1080/08916934.2017.1280027
https://pubmed.ncbi.nlm.nih.gov/28276715/
169. Dias, L. H., Miyamoto, S. T., Giovelli, R. A., de Magalhães, C., & Valim, V. (2021). Pain and fatigue are predictors of quality of life in primary Sjögren's syndrome. Advances in rheumatology (London, England), 61(1), 28. https://doi.org/10.1186/s42358-021-00181-9
https://pubmed.ncbi.nlm.nih.gov/34051867/ (Open Access)
https://advancesinrheumatology.biomedcentral.com/track/pdf/10.1186/s42358-021-00181-9.pdf
170. Lee, C. K., Tsai, C. P., Liao, T. L., Huang, W. N., Chen, Y. H., Lin, C. H., & Chen, Y. M. (2019). Overactive bladder and bladder pain syndrome/interstitial cystitis in primary Sjögren's syndrome patients: A nationwide population-based study. PloS one, 14(11), e0225455. https://doi.org/10.1371/journal.pone.0225455
https://pubmed.ncbi.nlm.nih.gov/31747429/ (Open Access)
171. Lee, K. L., Dong, C. S., Chen, M. Y., Ho, C. H., Tai, H. C., Hung, S. F., & Yu, H. J. (2011). Multifactorial causes of irritating bladder symptoms in patients with Sjögren's syndrome. Neurourology and urodynamics, 30(1), 97–101. https://doi.org/10.1002/nau.20887
https://pubmed.ncbi.nlm.nih.gov/20928912/
172. Carubbi, F., Alunno, A., Conforti, A., Riccucci, I., Di Cola, I., Bartoloni, E., & Gerli, R. (2020). Characterisation of articular manifestations in primary Sjögren's syndrome: clinical and imaging features. Clinical and experimental rheumatology, 38 Suppl 126(4), 166–173.
https://pubmed.ncbi.nlm.nih.gov/33025895/ (Open Access)
173. Nilsson, A. M., Aaltonen, H. L., Olsson, P., Persson, H. L., Hesselstrand, R., Theander, E., Wollmer, P., & Mandl, T. (2021). Mixed Airway and Pulmonary Parenchymal Disease in Patients With Primary Sjögren Syndrome: A 6-year Follow-up. The Journal of rheumatology, 48(2), 232–240. https://doi.org/10.3899/jrheum.200247
https://pubmed.ncbi.nlm.nih.gov/32541077/ (Open Access)
174. Ramponi G, Folci M, Badalamenti S, Angelini C, Brunetta E. Biomarkers and Diagnostic Testing for Renal Disease in Sjogren's Syndrome. Front Immunol. 2020 Sep 17;11:562101. doi: 10.3389/fimmu.2020.562101. PMID: 33042142; PMCID: PMC7527442.
https://pubmed.ncbi.nlm.nih.gov/33042142/ (Open Access)
175. Perzyńska-Mazan, J., Maślińska, M., & Gasik, R. (2018). Neurological manifestations of primary Sjögren's syndrome. Reumatologia, 56(2), 99–105. https://doi.org/10.5114/reum.2018.75521
https://pubmed.ncbi.nlm.nih.gov/29853725/ (Open Access)
176. Morreale, M., Marchione, P., Giacomini, P., Pontecorvo, S., Marianetti, M., Vento, C., Tinelli, E., & Francia, A. (2014). Neurological involvement in primary Sjögren syndrome: a focus on central nervous system. PloS one, 9(1), e84605. https://doi.org/10.1371/journal.pone.0084605
https://pubmed.ncbi.nlm.nih.gov/24465419/ (Open Access)
177. Mofors, J., Björk, A., Smedby, K. E., Kvarnström, M., Forsblad-d'Elia, H., Magnusson-Bucher, S., Eriksson, P., Mandl, T., Baecklund, E., Nordmark, G., & Wahren-Herlenius, M. (2020). Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies. Annals of the rheumatic diseases, 79(2), 307–308. https://doi.org/10.1136/annrheumdis-2019-216287
178. Sène, D., Cacoub, P., Authier, F. J., Haroche, J., Créange, A., Saadoun, D., Amoura, Z., Guillausseau, P. J., & Lefaucheur, J. P. (2013). Sjögren Syndrome-Associated Small Fiber Neuropathy: Characterization From a Prospective Series of 40 Cases. Medicine, 92(5), e10–e18. https://doi.org/10.1097/MD.0000000000000005
https://pubmed.ncbi.nlm.nih.gov/23982054/ (Open Access)
179. Gwathmey, K. G., & Pearson, K. T. (2019). Diagnosis and management of sensory polyneuropathy. BMJ (Clinical research ed.), 365, l1108. https://doi.org/10.1136/bmj.l1108
https://pubmed.ncbi.nlm.nih.gov/31068323/
180. Lefaucheur, J. P., Sène, D., & Oaklander, A. L. (2018). Primary Sjögren’s Syndrome. The New England journal of medicine, 379(1), 96. https://doi.org/10.1056/NEJMc1804598
https://pubmed.ncbi.nlm.nih.gov/29975035/
181. Farhad, K., & Oaklander, A. L. (2018). Fibromyalgia and small-fiber polyneuropathy: What's in a name?. Muscle & nerve, 58(5), 611–613. https://doi.org/10.1002/mus.26179
https://pubmed.ncbi.nlm.nih.gov/29938813/
182. Lodahl, M., Treister, R., & Oaklander, A. L. (2017). Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy. Pain reports, 3(1), e633. https://doi.org/10.1097/PR9.0000000000000633
https://pubmed.ncbi.nlm.nih.gov/29430562/ (Open Access)
183. Vitali, C., & Del Papa, N. (2015). Pain in primary Sjögren's syndrome. Best practice & research. Clinical rheumatology, 29(1), 63–70. https://doi.org/10.1016/j.berh.2015.05.002
https://pubmed.ncbi.nlm.nih.gov/26267000/
184. Oaklander, A. L., & Nolano, M. (2019). Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review. JAMA neurology, 76(10), 1240–1251. https://doi.org/10.1001/jamaneurol.2019.2917
https://pubmed.ncbi.nlm.nih.gov/31498378/
185. Kelley, M. A., & Hackshaw, K. V. (2021). Intraepidermal Nerve Fiber Density as Measured by Skin Punch Biopsy as a Marker for Small Fiber Neuropathy: Application in Patients with Fibromyalgia. Diagnostics (Basel, Switzerland), 11(3), 536. https://doi.org/10.3390/diagnostics11030536
https://pubmed.ncbi.nlm.nih.gov/33802768/ (Open Access)
186. Giles, I., & Isenberg, D. (2000). Fatigue in primary Sjögren's syndrome: is there a link with the fibromyalgia syndrome?. Annals of the rheumatic diseases, 59(11), 875–878. https://doi.org/10.1136/ard.59.11.875
https://pubmed.ncbi.nlm.nih.gov/11053064/ (Open Access)
187. Saldanha, I. J., Bunya, V. Y., McCoy, S. S., Makara, M., Baer, A. N., & Akpek, E. K. (2020). Ocular Manifestations and Burden Related to Sjögren Syndrome: Results of a Patient Survey. American journal of ophthalmology, 219, 40–48. https://doi.org/10.1016/j.ajo.2020.05.043
https://pubmed.ncbi.nlm.nih.gov/32569739/ (NOTE: see Table 5 for important QOL data)
188. Baer AN, Hammitt KM. Sjögren's disease, not syndrome. Arthritis Rheumatol. 2021 Feb 9. doi: 10.1002/art.41676. Epub ahead of print. PMID: 33559389.
https://pubmed.ncbi.nlm.nih.gov/33559389/
189. Vitali, C., Minniti, A., Pignataro, F., Maglione, W., & Del Papa, N. (2021). Management of Sjögren's Syndrome: Present Issues and Future Perspectives. Frontiers in medicine, 8, 676885. https://doi.org/10.3389/fmed.2021.676885
https://pubmed.ncbi.nlm.nih.gov/34164418/ (Open Access)
Updated 7-7-21